HOSPITAL UNIVERSITARIO RUBER
Departamento
David Geffen School of Medicine at UCLA
Los Ángeles, Estados UnidosPublicaciones en colaboración con investigadores/as de David Geffen School of Medicine at UCLA (20)
2024
-
Correction to: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer (npj Breast Cancer, (2022), 8, 1, (98), 10.1038/s41523-022-00467-1)
npj Breast Cancer
-
Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results from AMEERA-5
Journal of Clinical Oncology, Vol. 42, Núm. 22, pp. 2680-2690
-
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Annals of Oncology, Vol. 35, Núm. 1, pp. 66-76
2023
-
Construction and validation of a gene expression classifier to predict immunotherapy response in primary triple-negative breast cancer
Communications Medicine, Vol. 3, Núm. 1
-
DESTINY-Breast03 trial: some questions remain – Authors' reply
The Lancet
-
Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer
European Journal of Cancer, Vol. 178, pp. 23-33
-
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
The Lancet, Vol. 401, Núm. 10371, pp. 105-117
2022
-
AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer
Therapeutic Advances in Medical Oncology, Vol. 14
-
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
Breast Cancer Research and Treatment, Vol. 195, Núm. 2, pp. 127-139
-
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis
Cancers, Vol. 14, Núm. 20
-
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis
npj Breast Cancer, Vol. 8, Núm. 1
-
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
npj Breast Cancer, Vol. 8, Núm. 1
-
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
New England Journal of Medicine, Vol. 386, Núm. 12, pp. 1142-1154
2021
-
A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer
Future Oncology, Vol. 17, Núm. 30, pp. 3911-3924
-
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
Annals of Oncology, Vol. 32, Núm. 9, pp. 1148-1156
-
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer ☆
Annals of Oncology, Vol. 32, Núm. 12, pp. 1475-1495
-
Sacituzumab govitecan in metastatic triple-negative breast cancer
New England Journal of Medicine, Vol. 384, Núm. 16, pp. 1529-1541
2020
-
Oncological care organisation during COVID-19 outbreak
ESMO Open, Vol. 5, Núm. 4
2018
-
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2
European Journal of Cancer, Vol. 103, pp. 147-154
-
Paclitaxel with inhibitor of apoptosis antagonist, LCL161, for localized triple-negative breast cancer, prospectively stratified by gene signature in a biomarker-driven neoadjuvant trial
Journal of Clinical Oncology, Vol. 36, Núm. 31, pp. 3126-3133